Oncolytics Biotech (ONC) Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
More News related to ONC
- Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
- Oncolytics Biotech(R) Inc. Announces 2009 Third Quarter Results
- Oncolytics Biotech(R) Inc. Announces Results of Second Warrant Expiry Date Acceleration Program
- Media Advisory - Oncolytics Biotech(R) Inc. to Present at BIO-Europe 2009
- Oncolytics Biotech(R) Inc. Collaborators to Present Phase II Sarcoma Trial Results at CTOS Annual Meeting
Oncolytics Biotech Inc. (NASDAQ: ONC) announced that interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung were presented May 30, 2009 at the American Society of Clinical Oncology (ASCO) annual meeting. The meeting is being held in Orlando, Florida from May 29 to June 2, 2009.
The presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" was delivered by Dr. Monica Mita, the study principal investigator at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
